ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2025
DurAVR - a novel biomimetic balloon-expandable transcatheter valve for TAVI, valve-in-valve TAVI and redo-TAVI.
Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Innovation and Challenges in Materials for Transcatheter Aortic Valves.Journal of cardiovascular translational research · 2026Review
- Contemporary Management of Aortic Stenosis: Timing of Intervention and Lifetime Valve Management.European journal of clinical investigation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe DurAVR transcatheter heart valve (THV) is a novel biomimetic balloon-expandable valve with promising early clinical results.
aimsWe aimed to assess the hydrodynamic performance of the DurAVR THV in native, valve-in-valve (ViV), and redo-transcatheter aortic valve implantation (TAVI) procedures against commercially available THVs on the bench.
methodsThe hydrodynamic function of the DurAVR THV was assessed by simulating native valve deployments at 0 mm, 3 mm, and 6 mm depths, compared to SAPIEN 3 (S3), Evolut PRO, Navitor, and ACURATE neo2 (ACn2) valves. For ViV simulations, THVs were implanted in 21 mm and 23 mm Magna Ease, Mosaic, and Hancock bioprostheses. For redo-TAVI simulations, the DurAVR THV was assessed within S3, Evolut PRO, Navitor, and ACn2 valves.
resultsFor native TAVI simulations, the DurAVR THV demonstrated superior or comparable hydrodynamic performance, independent of implant depth, with an effective orifice area (EOA) ≥3 cm
conclusionsIn this bench study, the DurAVR THV demonstrated excellent hydrodynamic performance in native, ViV, and redo-TAVI simulations. Future large-scale studies are needed to confirm these findings in clinical application and further characterise the valve's short- and long-term performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.